Price T Rowe Associates Inc Entrada Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,753,357 shares of TRDA stock, worth $39.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,753,357
Previous 3,009,673
8.52%
Holding current value
$39.2 Million
Previous $45.4 Million
14.09%
% of portfolio
0.0%
Previous 0.01%
Shares
10 transactions
Others Institutions Holding TRDA
# of Institutions
76Shares Held
25.7MCall Options Held
0Put Options Held
0-
Baker Bros. Advisors LP New York, NY4.87MShares$69.3 Million0.87% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.43MShares$63.1 Million25.58% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$62.8 Million22.02% of portfolio
-
Black Rock Inc. New York, NY1.49MShares$21.2 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA1.28MShares$18.3 Million0.72% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $447M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...